NEW YORK–(BUSINESS WIRE)–Faruqi & Faruqi, LLP, a leading national securities law firm, reminds
investors in Boston Scientific Corporation (“Boston Scientific” or the
“Company”) (NYSE:BSX) of the June 24, 2019 deadline to seek the role of
lead plaintiff in a federal securities class action that has been filed
against the Company.

If you invested in Boston Scientific stock or options between
February 26, 2015 – April 16, 2019 and would like to discuss your
legal rights, click here: www.faruqilaw.com/BSX.
There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at
877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected].

The lawsuit has been filed in the U.S. District Court for the Southern
District of New York on behalf of all those who purchased Boston
Scientific securities between February 26, 2015 – April 16, 2019 (the
“Class Period”). The case, Klein v. Boston Scientific Corporation et
al., No. 19-cv-03642 was filed on April 24, 2019.

The lawsuit focuses on whether the Company and its executives violated
federal securities laws by making false and/or misleading statements
and/or failing to disclose that: (1) Boston Scientific’s surgical mesh
products indicated for the transvaginal repair of pelvic organ prolapse
(“POP”) were unsafe; (2) accordingly, Boston Scientific’s continued
marketing and sales of these devices in the United States was unlikely
to be sustainable; (3) separately, the Company had sold vaginal mesh
implants containing counterfeit or adulterated resin products imported
from China; (4) the foregoing conduct subjected the Company to a
heightened risk of regulatory scrutiny and/or government investigations;
and (5) as a result, the Company’s public statements were materially
false and misleading at all relevant times.

On April 16, 2019, the Food and Drug Administration (“FDA”) announced
that it had “ordered the manufacturers of all remaining surgical mesh
products indicated for the transvaginal repair of pelvic organ prolapse
. . . to stop selling and distributing their products in the U.S.
immediately.” The FDA stated that “the manufacturers, Boston Scientific
and Coloplast, have not demonstrated a reasonable assurance of safety
and effectiveness for these devices,” as required to continue marketing
the devices in the United States.

On this news, the Company’ stock price fell, over two trading sessions,
from $37.81 per share on April 16, 2019 to $34.91 per share on April 17,
2019—a $2.90 or 7.67% drop.

The court-appointed lead plaintiff is the investor with the largest
financial interest in the relief sought by the class who is adequate and
typical of class members who directs and oversees the litigation on
behalf of the putative class. Any member of the putative class may move
the Court to serve as lead plaintiff through counsel of their choice, or
may choose to do nothing and remain an absent class member. Your ability
to share in any recovery is not affected by the decision to serve as a
lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding
Boston Scientific’s conduct to contact the firm, including
whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is
Faruqi & Faruqi, LLP (www.faruqilaw.com).
Prior results do not guarantee or predict a similar outcome with respect
to any future matter. We welcome the opportunity to discuss your
particular case. All communications will be treated in a confidential
manner.

Contacts

FARUQI & FARUQI, LLP
685 Third Avenue, 26^th Floor
New
York, NY 10017
Attn: Richard Gonnello, Esq.
[email protected]
Telephone:
(877) 247-4292 or (212) 983-9330